Canadian application, no grantCanada
Treatment of sle with dehydroepiandrosterone
CA 2388705 A1 · Owner: Genelabs Technologies, Inc. · Inventors: Schwartz, Kenneth E.; Gurwith, Marc J.
Overview
Drawings and full text
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
This invention provides a method of treating systemic lupus erythematosus (SLE) with (DHEA) and a related pharmaceutical product.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed November 13, 2000. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended November 13, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by November 13, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
FiledNovember 13, 2000
GrantedNo grant recorded
Term endedNovember 13, 2020
Patent numberCA 2388705 A1
Classification (IPC)A61K31/56 +2 more
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.